324 related articles for article (PubMed ID: 21729319)
1. Targeting insulin-like growth factor axis in hepatocellular carcinoma.
Wu J; Zhu AX
J Hematol Oncol; 2011 Jul; 4():30. PubMed ID: 21729319
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
3. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
Ngo MT; Jeng HY; Kuo YC; Diony Nanda J; Brahmadhi A; Ling TY; Chang TS; Huang YH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669204
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
5. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
6. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
7. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage.
Tovar V; Alsinet C; Villanueva A; Hoshida Y; Chiang DY; Solé M; Thung S; Moyano S; Toffanin S; Mínguez B; Cabellos L; Peix J; Schwartz M; Mazzaferro V; Bruix J; Llovet JM
J Hepatol; 2010 Apr; 52(4):550-9. PubMed ID: 20206398
[TBL] [Abstract][Full Text] [Related]
8. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
Negi A; Ramarao P; Kumar R
Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
[TBL] [Abstract][Full Text] [Related]
9. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.
Breuhahn K; Schirmacher P
World J Gastroenterol; 2008 Mar; 14(11):1690-8. PubMed ID: 18350600
[TBL] [Abstract][Full Text] [Related]
11. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
[TBL] [Abstract][Full Text] [Related]
12. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
13. Development of the phenylpyrazolo[3,4-
Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
[No Abstract] [Full Text] [Related]
14. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
[TBL] [Abstract][Full Text] [Related]
15. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells.
Shimizu M; Shirakami Y; Sakai H; Tatebe H; Nakagawa T; Hara Y; Weinstein IB; Moriwaki H
Cancer Lett; 2008 Apr; 262(1):10-8. PubMed ID: 18164805
[TBL] [Abstract][Full Text] [Related]
16. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
17. A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines.
Freise C; Ruehl M; Erben U; Neumann U; Seehofer D; Kim KY; Trowitzsch-Kienast W; Stroh T; Zeitz M; Somasundaram R
BMC Complement Altern Med; 2011 May; 11():39. PubMed ID: 21569410
[TBL] [Abstract][Full Text] [Related]
18. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
[TBL] [Abstract][Full Text] [Related]
19. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.
Huang HJ; Angelo LS; Rodon J; Sun M; Kuenkele KP; Parsons HA; Trent JC; Kurzrock R
PLoS One; 2011; 6(10):e26060. PubMed ID: 22022506
[TBL] [Abstract][Full Text] [Related]
20. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
